Compare UXIN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | EBS |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 413.3M |
| IPO Year | 2018 | 2006 |
| Metric | UXIN | EBS |
|---|---|---|
| Price | $1.39 | $7.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 233.5K | ★ 656.7K |
| Earning Date | 04-10-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | $245.77 | $1.29 |
| Revenue Next Year | $44.72 | N/A |
| P/E Ratio | ★ $4.05 | $103.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.25 | $5.87 |
| 52 Week High | $4.50 | $14.06 |
| Indicator | UXIN | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 36.07 | 39.76 |
| Support Level | N/A | N/A |
| Resistance Level | $3.15 | $8.59 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 26.16 | 31.03 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.